Alterations in Gut Microbiota Are Correlated With Serum Metabolites in Patients With Insomnia Disorder.

Front Cell Infect Microbiol

Department of Health Management, Henan Key Laboratory of Chronic Disease Health Management, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, China.

Published: April 2022

This study aimed to investigate insomnia-related alterations in gut microbiota and their association with serum metabolites. A total of 24 patients with insomnia disorder and 22 healthy controls were recruited. The fecal and serum samples were collected. The 16s rRNA sequencing and bioinformatics analysis were conducted to explore insomnia-related changes in the diversity, structure, and composition of the gut microbiota. UPLC-MS was performed to identify insomnia-related serum metabolites. Spearman correlation analysis was used to investigate the correlations between insomnia-related gut bacteria and the serum metabolites. Despite the nonsignificant changes in the diversity and structure of gut microbiota, insomnia disorder patients had significantly decreased family , family , and genus , along with significantly increased family and genus , compared with healthy controls. Genus and genus were dominant in patients with insomnia disorder, whereas genus , genus , genus , and family were dominant in healthy controls. The UPLC-MS analysis identified 97 significantly decreased metabolites and 74 significantly increased metabolites in the serum samples of patients with insomnia disorder, compared with those of healthy controls. KEGG enrichment analysis revealed 1 significantly upregulated metabolic pathway and 16 downregulated metabolic pathways in patients with insomnia disorder. Furthermore, Spearman correlation analysis unveiled significant correlations among the altered bacteria genus and serum metabolites. Patients with insomnia disorder have differential gut microbiota and serum metabolic profiles compared with healthy controls. The alterations in gut microbiota were correlated with specific serum metabolites, suggesting that some serum metabolites might mediate gut microbiota-brain communication in the pathogenesis of insomnia disorder.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892143PMC
http://dx.doi.org/10.3389/fcimb.2022.722662DOI Listing

Publication Analysis

Top Keywords

insomnia disorder
32
serum metabolites
28
gut microbiota
24
patients insomnia
24
healthy controls
20
alterations gut
12
compared healthy
12
genus genus
12
serum
10
metabolites
9

Similar Publications

Glucocorticoid resistance syndrome (GRS) is caused by inactivating pathogenic variants in the glucocorticoid receptor gene . Reduced glucocorticoid receptor signaling leads to decreased tissue sensitivity to cortisol and resultant biochemical hypercortisolism without the classic clinical features of Cushing syndrome. Patients variably present with signs and symptoms of mineralocorticoid and androgen excess from ACTH overstimulation of the adrenal cortex.

View Article and Find Full Text PDF

Background: Sleep insufficiency is known to negatively impact on glucose metabolism. Consequently, there is interest in determining the impact of improving sleep on glucose metabolism. We conducted a meta-analysis of studies that aimed at improving sleep using cognitive behavioural therapy for insomnia (CBT-I) and/or sleep hygiene or sleep extension on glucose metabolism.

View Article and Find Full Text PDF

Comparing Effects of Aromatherapy with Five Herbs Essential Oils on PCPA-induced Insomnia Mice.

J Microbiol Biotechnol

November 2024

Hua An Tang Biotech Group Co., Ltd., Guangzhou 510000, P.R. China.

Delayed treatment of insomnia-related symptoms can harm physical health and increase the psychological burden. In addition to oral medications and some physical therapies, aromatherapy can help overcome some treatment-related side effects. Herein, parachlorophenylalanine (PCPA)-induced insomnia was established in Kunming (KM) mice, which were subjected to aromatherapy using five plants (, , , , and ) essential oils (EOs).

View Article and Find Full Text PDF

The Association Between Insomnia and Temporomandibular Disorders in Orthodontic Patients.

J Pain Res

January 2025

State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Objective: This cross-sectional study aimed to investigate the association between insomnia and the presence of temporomandibular disorders (TMD) and its subtypes in orthodontic patients.

Methods: A total of 648 adult orthodontic patients (158 males and 490 females, median age 26) were included and completed a questionnaire containing sociodemographic information, insomnia severity index (ISI), the five major temporomandibular disorder symptoms (5Ts) checklist, and self-reported sleep bruxism. Presence of insomnia and TMD of the included patients was determined according to the diagnostic criteria, and statistical analyses were conducted as appropriate to compare ISI-related scores between TMD and non-TMD participants.

View Article and Find Full Text PDF

Effect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.

BMC Pharmacol Toxicol

January 2025

Department of Community Medicine, Islamic International Medical College (IIMC), Riphah International University, Rawalpindi, Pakistan.

Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.

Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!